Development and pilot evaluation of a new nanoparticle-capture workflow for doxorubicin-induced toxicity biomarker identification

Emanuel F. Petricoin, Mark M. Ross, Weidong Zhou, Davide Tamburro, Alessandra Luchini, Lance A. Liotta, Eugene H. Herman, Rebecca E. Scully, Tracie L Miller, Vivian I. Franco, Stephen E. Sallan, Steven E Lipshultz

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Cardiotoxicity related to doxorubicin chemotherapy is a major late effect in childhood cancer survivors. Serum cardiac troponin concentrations (cTnT) can be elevated during doxorubicin therapy but the cellular associations with this myocardial injury are not well understood. We evaluate a novel nanotechnology-based biomarker discovery approach on a pilot set of serial serum samples from 11 children with acute lymphoblastic leukemia receiving doxorubicin therapy to determine if a proteomic signature of myocardial injury could be identified. This nanoparticle-based biomarker capture technology was utilized to analyze 40 serial serum samples from these children, 3 of whom seroconverted, 2 from cTnT-negative to cTnT-positive and 1 from cTnT-positive to cTnT-negative. High-resolution mass spectrometry analysis of the captured material identified 13 differentially expressed candidate proteins, whose spectral count values reflected changes in cTnT concentrations, which were verified in the serum samples from the 3 consistently cTnT-negative and 5 consistently cTnT-positive children. Of the 13 candidate proteins, 5 were significantly elevated (p.

Original languageEnglish (US)
JournalProgress in Pediatric Cardiology
DOIs
StateAccepted/In press - 2016

Keywords

  • Cardiotoxicity
  • Childhood-Cancer
  • Nanoparticle-capture
  • Pediatric

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Development and pilot evaluation of a new nanoparticle-capture workflow for doxorubicin-induced toxicity biomarker identification'. Together they form a unique fingerprint.

  • Cite this

    Petricoin, E. F., Ross, M. M., Zhou, W., Tamburro, D., Luchini, A., Liotta, L. A., Herman, E. H., Scully, R. E., Miller, T. L., Franco, V. I., Sallan, S. E., & Lipshultz, S. E. (Accepted/In press). Development and pilot evaluation of a new nanoparticle-capture workflow for doxorubicin-induced toxicity biomarker identification. Progress in Pediatric Cardiology. https://doi.org/10.1016/j.ppedcard.2015.10.005